Not provided
Not provided
Not provided
Not provided
COVID-19 pandemic and philips cpap machine recall
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Philips Respironics | INDUSTRY |
| Fundação de Amparo à Pesquisa do Estado de São Paulo | OTHER_GOV |
| Conselho Nacional de Desenvolvimento Científico e Tecnológico | OTHER_GOV |
Not provided
Not provided
Not provided
Despite the advances in the treatment of acute cardiogenic pulmonary edema (ACPE), the readmissions rates and cardiovascular events remain very high. In this context, it is possible that other potential risk factors may influence the poor prognosis of the ACPE. One of these potential candidates is Obstructive Sleep Apnea(OSA). This study was designed to evaluate the impact of OSA treatment with CPAP in consecutive patients with ACPE. The primary outcome will be to evaluate the impact of CPAP on the recurrence of ACPE in the 1-year follow-up.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CPAP | Active Comparator | Continuous positive airway pressure |
|
| Nasal strips | Sham Comparator | Nasal Strips |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CPAP | Device | This is the standard treatment for OSA. |
| |
| Nasal Strips |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of ACPE recurrence | To evaluate the effects of CPAP on the recurrence of ACPE as compared to placebo | 1-year |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of all-cause mortality | To evaluate the effects of CPAP on the all-cause mortality as compared to placebo | 1-year |
| Rate of cardiovascular mortality | To evaluate the effects of CPAP on the cardiovascular mortality as compared to placebo |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| PROCAPE - University of Pernambuco | Recife | São Paulo | Brazil | |||
| Hospital Samaritano |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Device |
Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo. |
|
| 1-year |
| Number of new hospital admissions | To evaluate the effects of CPAP on the number of new hospital admissions as compared to placebo | 1-year |
| Blood pressure effects ( (mmHg) | To evaluate the effects of CPAP on the blood pressure reduction as compared to placebo | 1-year |
| Levels of BNP levels (pg/ml) | To evaluate the effects of CPAP on the BNP levels as compared to placebo | 1-year |
| Cardiac function (left ventricular ejection fraction - %) | To evaluate the effects of CPAP on the left ventricular ejection fraction (by echocardiography) as compared to placebo | 1-year |
| São Paulo |
| São Paulo |
| Brazil |
| Heart Institute (InCor) | São Paulo | 05049000 | Brazil |
| Hospital Dante Pazzanese | São Paulo | Brazil |
| ID | Term |
|---|---|
| D020181 | Sleep Apnea, Obstructive |
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D012891 | Sleep Apnea Syndromes |
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided